In this issue

INDIAN BIOSERVICES INDUSTRY HITS RS 29,000 CR WITH 12% GROWTH IN 2019-20

Indian BioServices industry comprising over 1000 players in the field of clinical research, contract research, contract development and manufacturing has seen significant growth in the recent past and witnessed a 12 per cent growth in 2019-20 by reaching Rs 29,120 crore as against 19 per cent growth recorded in 2018-19. Contract research, development and manufacturing are contributing the most in BioServices industry with less than 10 per cent coming from clinical research organisations.

For Feedback, please email us at : communications@mmactiv.com
--

Premas Biotech, Oramed Announce Oral Covid-19 Vaccine Candidate

Gurugram based Premas Biotech has announced the development of an oral COVID-19 vaccine that has shown efficacy after a single dose, in conjunction with Jerusalem-based Oramed Pharmaceuticals Inc.

1 min

Is India's War On Covid-19 Losing Steam?

As the vaccination drive continues, India is faced with a shortage of vaccines considering the population of the country, which currently stands at a staggering 1,390,605,073, as per Worldometer elaboration of the latest United Nations data. The Indian government, to address this stark reality, has opened its doors to foreign vaccines and are fast-tracking their approval.

8 mins

“India should focus on innovating drugs and molecules to emerge as a global leader”

The Organisation of Pharmaceutical Producers of India (OPPI) has elected S Sridhar as its next President for a period of two years, effective from February 15, 2021. He takes over from Sharad Tyagi, Former Managing Director, Boehringer Ingelheim India Pvt Ltd. Sridhar is currently serving as the Managing Director of Pfizer Limited and is heading Pfizer Inc’s commercial business in India. Sridhar has been a member of the Executive Committee of OPPI for the past six years and has also chaired its Finance and Taxation Work Group. He is a strong voice of healthcare transformation in the country and was the chair of FICCI’s Pharma Committee till recently. In conversation with BioSpectrum, S Sridhar talks about making a difference to patients, the industry and the country via this new role.

2 mins

“Made in India products need an ecosystem for commercialisation of innovations”

Established in 1998, Ernakulam-based Agappe Diagnostics is one of the rapidly growing companies in the in vitro diagnostic (IVD) industry in India, having a wide range of products in the pre-analytical and analytical segment. Focused on research, design, and production of clinical chemistry reagents and instrument, Agappe has over 1000 distributors and holds a significant place in the global original equipment manufacturer (OEM) business. The company currently has a workforce of more than 600 employees spread across sectors such as R&D, manufacturing, sales, support and operations. In conversation with BioSpectrum, Thomas John, Managing Director, Agappe Diagnostics, Ernakulam shares his strategies and plans for the company’s growth in the long run.

4 mins

Thermo Fisher unveils human plasma-like cell culture medium

Thermo Fisher Scientific has launched the new Gibco Human Plasma-like Medium (HPLM), the first cell culture medium on the market that mimics the metabolic profile of human plasma that is designed to provide researchers with a realistic view of cell growth within the human body.

1 min

Vocalising pain is a must

Women have unique health issues. In fact, some of the health issues that affect both men and women can affect women very differently.

3 mins

Read all stories from Bio Spectrum

Bio Spectrum Magazine Description:

India's leading publication that covers the business of bio-technology. With comprehensive analyses of policy issues, products and services across the bio-pharma, bio-informatics, bio-infrastructure and bio-agriculture segments, it is the industry's most authoritative source of information.